Compugen Ltd. (CGEN)
Market Cap | 151.31M |
Revenue (ttm) | n/a |
Net Income (ttm) | n/a |
Shares Out | 89.53M |
EPS (ttm) | -0.18 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 144,820 |
Open | 1.750 |
Previous Close | 1.750 |
Day's Range | 1.680 - 1.750 |
52-Week Range | 0.530 - 3.030 |
Beta | 2.71 |
Analysts | Strong Buy |
Price Target | 7.00 (+314.2%) |
Earnings Date | Aug 5, 2024 |
About CGEN
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic... [Read more]
Financial Performance
In 2023, Compugen's revenue was $33.46 million, an increase of 346.12% compared to the previous year's $7.50 million. Losses were -$18.75 million, -44.34% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CGEN stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 314.20% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/1/q/conf8-2481550.jpg)
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
![](https://cdn.snapi.dev/images/v1/p/x/press6-2453230.jpg)
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening th...
![](https://cdn.snapi.dev/images/v1/p/r/press11-2439236.jpg)
Compugen Reports First Quarter 2024 Results
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsatell...
![](https://cdn.snapi.dev/images/v1/9/p/press13-2434272.jpg)
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
HOLON, Israel, May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the...
![](https://cdn.snapi.dev/images/v1/z/a/press15-2431628.jpg)
Compugen Appoints David Silberman as Chief Financial Officer
HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...
![](https://cdn.snapi.dev/images/v1/6/s/conf11-2411467.jpg)
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced tha...
![](https://cdn.snapi.dev/images/v1/l/y/conf3-2390567.jpg)
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced...
![](https://cdn.snapi.dev/images/v1/v/a/press20-2364790.jpg)
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
![](https://cdn.snapi.dev/images/v1/w/y/conf5-2353833.jpg)
Compugen to Participate in Two Upcoming Investor Conferences
HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...
![](https://cdn.snapi.dev/images/v1/a/p/press10-2317442.jpg)
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
![](https://cdn.snapi.dev/images/v1/n/m/conf11-2310490.jpg)
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
HOLON, Israel , March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
![](https://cdn.snapi.dev/images/v1/q/u/press7-2308101.jpg)
Compugen Reports Fourth Quarter and Full Year 2023 Results
Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple da...
![](https://cdn.snapi.dev/images/v1/u/p/conf12-2293132.jpg)
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
HOLON, Israel , Feb. 26, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced t...
![](https://cdn.snapi.dev/images/v1/s/l/conf14-2283101.jpg)
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
HOLON, Israel , Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd.
![](https://cdn.snapi.dev/images/v1/q/b/press4-2277677.jpg)
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
HOLON, Israel , Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced ...
![](https://cdn.snapi.dev/images/v1/k/9/press10-2219890.jpg)
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced th...
![](https://cdn.snapi.dev/images/v1/e/u/press15-2219847.jpg)
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOLON, Israel , Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today th...
![](https://cdn.snapi.dev/images/v1/d/u/biotech32-2201572.jpg)
Compugen stock rockets on anti-tumor drug deal with Gilead
Compugen Ltd.'s stock CGEN, -3.36% was up by 113% in premarket trading on Tuesday after the company said it agreed to sell exclusive rights to Gilead Sciences Inc. GILD, -1.03% for later stage develop...
![](https://cdn.snapi.dev/images/v1/q/r/press14-2201587.jpg)
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Dosing of first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody, will trigger $10 million milestone payment from AstraZeneca HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- C...
![](https://cdn.snapi.dev/images/v1/2/h/conf6-2201576.jpg)
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Conference call today, December 19, 2023, 8:30 AM ET to discuss the license agreement HOLON, Israel , Dec. 19, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer im...
![](https://cdn.snapi.dev/images/v1/p/r/press9-2201631.jpg)
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
FOSTER CITY, Calif. & HOLON, Israel--(BUSINESS WIRE)--Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program.
![](https://cdn.snapi.dev/images/v1/v/h/press17-2143565.jpg)
Compugen Reports Third Quarter 2023 Results
Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in co...
![](https://cdn.snapi.dev/images/v1/o/l/press19-2141148.jpg)
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations m...
![](https://cdn.snapi.dev/images/v1/w/a/press9-2140029.jpg)
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today th...
![](https://cdn.snapi.dev/images/v1/n/d/conf3-2130401.jpg)
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor si...